Wednesday, June 7, 2017

Leukemia - Table of Contents alert Volume 31 Issue 6

If you are unable to see the message below, click here to view.



Volume 31, Issue 6 (June 2017)

In this issue
Original Articles
Letters To The Editor

Also new
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed
Follow on Twitter
Celebrating 30 years of Leukemia — 1987 to 2017

Thank you to the editors, board members, contributors, reviewers and readers, past and present for their invaluable contributions, and for bringing the journal to this milestone.

Watch our anniversary video showing a brief impact overview >>>



How good are we at predicting the fate of someone with acute myeloid leukaemia?

E Estey and R P Gale

Leukemia 2017 31: 1255-1258; advance online publication, March 17, 2017; 10.1038/leu.2017.56

Full Text



The emerging roles of tumor-derived exosomes in hematological malignancies

M Boyiadzis and T L Whiteside

Leukemia 2017 31: 1259-1268; advance online publication, March 21, 2017; 10.1038/leu.2017.91

Abstract | Full Text

Original Articles



Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia

C Dafflon, V J Craig, H Méreau, J Gräsel, B Schacher Engstler, G Hoffman, F Nigsch, S Gaulis, L Barys, M Ito, J Aguadé-Gorgorió, B Bornhauser, J-P Bourquin, A Proske, C Stork-Fux, M Murakami, W R Sellers, F Hofmann, J Schwaller and R Tiedt

Leukemia 2017 31: 1269-1277; advance online publication, November 14, 2016; 10.1038/leu.2016.327

Abstract | Full Text

Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia

A-K Eisfeld, J Kohlschmidt, S Schwind, D Nicolet, J S Blachly, S Orwick, C Shah, M Bainazar, K W Kroll, C J Walker, A J Carroll, B L Powell, R M Stone, J E Kolitz, M R Baer, A de la Chapelle, K Mrózek, J C Byrd and C D Bloomfield

Leukemia 2017 31: 1278-1285; advance online publication, November 15, 2016; 10.1038/leu.2016.332

Abstract | Full Text

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis

F Thol, S Klesse, L Köhler, R Gabdoulline, A Kloos, A Liebich, M Wichmann, A Chaturvedi, J Fabisch, V I Gaidzik, P Paschka, L Bullinger, G Bug, H Serve, G Göhring, B Schlegelberger, M Lübbert, H Kirchner, M Wattad, D Kraemer, B Hertenstein, G Heil, W Fiedler, J Krauter, R F Schlenk, K Döhner, H Döhner, A Ganser and M Heuser

Leukemia 2017 31: 1286-1295; advance online publication, November 24, 2016; 10.1038/leu.2016.345

Abstract | Full Text

p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status

A Quintás-Cardama, C Hu, A Qutub, Y H Qiu, X Zhang, S M Post, N Zhang, K Coombes and S M Kornblau

Leukemia 2017 31: 1296-1305; advance online publication, November 25, 2016; 10.1038/leu.2016.350

Abstract | Full Text

Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure

M Wattad, D Weber, K Döhner, J Krauter, V I Gaidzik, P Paschka, M Heuser, F Thol, T Kindler, M Lübbert, H R Salih, A Kündgen, H-A Horst, P Brossart, K Götze, D Nachbaur, C-H Köhne, M Ringhoffer, G Wulf, G Held, H Salwender, A Benner, A Ganser, H Döhner and R F Schlenk for the German-Austrian AMLSG

Leukemia 2017 31: 1306-1313; advance online publication, January 19, 2017; 10.1038/leu.2017.23

Abstract | Full Text


Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway

Y Shen, C S Park, K Suppipat, T-A Mistretta, M Puppi, T M Horton, K Rabin, N S Gray, J P P Meijerink and H D Lacorazza

Leukemia 2017 31: 1314-1324; advance online publication, November 22, 2016; 10.1038/leu.2016.339

Abstract | Full Text


Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia

S E Karol, E Larsen, C Cheng, X Cao, W Yang, L B Ramsey, C A Fernandez, J R McCorkle, S W Paugh, R J Autry, E Lopez-Lopez, B Diouf, S Jeha, C-H Pui, E A Raetz, N J Winick, W L Carroll, S P Hunger, M L Loh, M Devidas, W E Evans, J J Yang and M V Relling

Leukemia 2017 31: 1325-1332; advance online publication, January 18, 2017; 10.1038/leu.2017.24

Abstract | Full Text


Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib OPEN

J Yu, L Chen, B Cui, Christina Wu, M Y Choi, Y Chen, L Zhang, L Z Rassenti, G F Widhopf II and T J Kipps

Leukemia 2017 31: 1333-1339; advance online publication, December 1, 2016; 10.1038/leu.2016.368

Abstract | Full Text

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

T M Herndon, S-S Chen, N S Saba, J Valdez, C Emson, M Gatmaitan, X Tian, T E Hughes, C Sun, D C Arthur, M Stetler-Stevenson, C M Yuan, C U Niemann, G E Marti, G Aue, S Soto, M Z H Farooqui, S E M Herman, N Chiorazzi and A Wiestner

Leukemia 2017 31: 1340-1347; advance online publication, January 11, 2017; 10.1038/leu.2017.11

Abstract | Full Text

Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia

E J Murphy, D S Neuberg, L Z Rassenti, G Hayes, R Redd, C Emson, K Li, J R Brown, W G Wierda, S Turner, A W Greaves, C S Zent, J C Byrd, C McConnel, J Barrientos, N Kay, M K Hellerstein, N Chiorazzi, T J Kipps and K R Rai

Leukemia 2017 31: 1348-1354; advance online publication, January 24, 2017; 10.1038/leu.2017.34

Abstract | Full Text


Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia

C Baer, F Dicker, W Kern, T Haferlach and C Haferlach

Leukemia 2017 31: 1355-1362; advance online publication, November 14, 2016; 10.1038/leu.2016.330

Abstract | Full Text


IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)

J Krönke, F Kuchenbauer, M Kull, V Teleanu, L Bullinger, D Bunjes, A Greiner, S Kolmus, S Köpff, M Schreder, L-O Mügge, C Straka, M Engelhardt, H Döhner, H Einsele, F Bassermann, R Bargou, S Knop and C Langer

Leukemia 2017 31: 1363-1367; advance online publication, December 26, 2016; 10.1038/leu.2016.384

Abstract | Full Text

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR OPEN

W-J Chng, H Goldschmidt, M A Dimopoulos, P Moreau, D Joshua, A Palumbo, T Facon, H Ludwig, L Pour, R Niesvizky, A Oriol, L Rosiñol, A Suvorov, G Gaidano, T Pika, K Weisel, V Goranova-Marinova, H H Gillenwater, N Mohamed, S Feng, S Aggarwal and R Hájek

Leukemia 2017 31: 1368-1374; advance online publication, December 27, 2016; 10.1038/leu.2016.390

Abstract | Full Text

Impact of pretransplant induction therapy on autologous stem cell transplantation for patients with newly diagnosed POEMS syndrome

J Li, M-H Duan, C Wang, X-F Huang, W Zhang, X-X Cao, T-N Zhu, J-L Zhuang, B Han, H Cai, H-C Cai and D-B Zhou

Leukemia 2017 31: 1375-1381; advance online publication, January 19, 2017; 10.1038/leu.2017.27

Abstract | Full Text


Loss of p300 accelerates MDS-associated leukemogenesis

G Cheng, F Liu, T Asai, F Lai, N Man, H Xu, S Chen, S Greenblatt, P-J Hamard, K Ando, X Chen, L Wang, C Martinez, M Tadi, L Wang, M Xu, F-C Yang, R Shiekhattar and S D Nimer

Leukemia 2017 31: 1382-1390; advance online publication, November 24, 2016; 10.1038/leu.2016.347

Abstract | Full Text

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium

A M Zeidan, N Al Ali, J Barnard, E Padron, J E Lancet, M A Sekeres, D P Steensma, A DeZern, G Roboz, E Jabbour, G Garcia-Manero, A List and R Komrokji

Leukemia 2017 31: 1391-1397; advance online publication, January 23, 2017; 10.1038/leu.2017.33

Abstract | Full Text


In vitro and in vivo assessment of direct effects of simulated solar and galactic cosmic radiation on human hematopoietic stem/progenitor cells

C Rodman, G Almeida-Porada, S K George, J Moon, S Soker, T Pardee, M Beaty, P Guida, S P Sajuthi, C D Langefeld, S J Walker, P F Wilson and C D Porada

Leukemia 2017 31: 1398-1407; advance online publication, November 24, 2016; 10.1038/leu.2016.344

Abstract | Full Text


Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis

C Ustun, F Giannotti, M-J Zhang, H-L Wang, C Brunstein, M Labopin, V Rocha, M de Lima, F Baron, B M Sandmaier, M Eapen, E Gluckman, A Nagler, D J Weisdorf and A Ruggeri

Leukemia 2017 31: 1408-1414; advance online publication, January 25, 2017; 10.1038/leu.2017.42

Abstract | Full Text


Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations

W Liu, W-M Yu, J Zhang, R J Chan, M L Loh, Z Zhang, K D Bunting and C-K Qu

Leukemia 2017 31: 1415-1422; advance online publication, November 14, 2016; 10.1038/leu.2016.326

Abstract | Full Text

PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis OPEN

M J Carter, K L Cox, S J Blakemore, A H Turaj, R J Oldham, L N Dahal, S Tannheimer, F Forconi, G Packham and M S Cragg

Leukemia 2017 31: 1423-1433; advance online publication, November 15, 2016; 10.1038/leu.2016.333

Abstract | Full Text

Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells

F Yan, N Shen, J X Pang, Y W Zhang, E Y Rao, A M Bode, A Al-Kali, D E Zhang, M R Litzow, B Li and S J Liu

Leukemia 2017 31: 1434-1442; advance online publication, November 25, 2016; 10.1038/leu.2016.349

Abstract | Full Text

Letters To The Editor


CBFβ-SMMHC regulates ribosomal gene transcription and alters ribosome biogenesis

G Cordonnier, A Mandoli, A Radhouane, G Hypolite, L Lhermitte, M Belhocine, V Asnafi, E Macintyre, J H A Martens, S Fumagalli and J Bond

Leukemia 2017 31: 1443-1446; advance online publication, February 15, 2017; 10.1038/leu.2017.53

Full Text

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma OPEN

J Martinez-Lopez, B Sanchez-Vega, S Barrio, I Cuenca, Y Ruiz-Heredia, R Alonso, I Rapado, C Marin, M-T Cedena, B Paiva, N Puig, M-V Mateos, R Ayala, M-T Hernández, C Jimenez, L Rosiñol, R Martínez, A-I Teruel, N Gutiérrez, M-L Martin-Ramos, A Oriol, J Bargay, J Bladé, J San-Miguel, R Garcia-Sanz and J-J Lahuerta

Leukemia 2017 31: 1446-1449; advance online publication, February 17, 2017; 10.1038/leu.2017.58

Full Text

Impact of treatment site on disparities in outcome among adolescent and young adults with Hodgkin lymphoma

J Wolfson, C-L Sun, L Wyatt, W Stock and S Bhatia

Leukemia 2017 31: 1450-1453; advance online publication, February 20, 2017; 10.1038/leu.2017.66

Full Text

Phosphatase PRL2 promotes AML1-ETO-induced acute myeloid leukemia

M Kobayashi, S Chen, Y Bai, C Yao, R Gao, X-J Sun, C Mu, T A Twiggs, Z-H Yu, H S Boswell, M C Yoder, R Kapur, J C Mulloy, Z-Y Zhang and Y Liu

Leukemia 2017 31: 1453-1457; advance online publication, February 21, 2017; 10.1038/leu.2017.67

Full Text

Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997–2013

S Lehmann, S Deneberg, P Antunovic, Å Rangert-Derolf, H Garelius, V Lazarevic, K Myhr-Eriksson, L Möllgård, B Uggla, A Wahlin, L Wennström, M Höglund and G Juliusson

Leukemia 2017 31: 1457-1459; advance online publication, February 24, 2017; 10.1038/leu.2017.71

Full Text

Decreased spermatogonial quantity in prepubertal boys with leukaemia treated with alkylating agents OPEN

M Poganitsch-Korhonen, I Masliukaite, M Nurmio, P Lähteenmäki, M van Wely, A M M van Pelt, K Jahnukainen and J-B Stukenborg

Leukemia 2017 31: 1460-1463; advance online publication, March 8, 2017; 10.1038/leu.2017.76

Full Text

Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma

H Einsele, S Knop, M Vogel, J Müller, M Kropff, B Metzner, C Langer, H Sayer, W Jung, H A Dürk, H Salwender, H Wandt, F Bassermann, M Gramatzki, W Rösler, H-H Wolf, W Brugger, M Engelhardt, T Fischer, P Liebisch and C Straka

Leukemia 2017 31: 1463-1466; advance online publication, March 15, 2017; 10.1038/leu.2017.83

Full Text

A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML

L M Kats, S J Vervoort, R Cole, A J Rogers, G P Gregory, E Vidacs, J Li, R Nagaraja, K E Yen and R W Johnstone

Leukemia 2017 31: 1466-1470; advance online publication, March 10, 2017; 10.1038/leu.2017.84

Full Text

ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma

A Dzikiewicz-Krawczyk, K Kok, I Slezak-Prochazka, J-L Robertus, J Bruining, M M Tayari, B Rutgers, D de Jong, J Koerts, A Seitz, J Li, B Tillema, J E Guikema, I M Nolte, A Diepstra, L Visser, J Kluiver and A van den Berg

Leukemia 2017 31: 1470-1473; advance online publication, March 23, 2017; 10.1038/leu.2017.94

Full Text

No evidence for microsatellite instability in acute myeloid leukemia

C J Walker, A-K Eisfeld, L K Genutis, M Bainazar, J Kohlschmidt, K Mrózek, A J Carroll, J E Kolitz, B L Powell, E S Wang, R M Stone, R Bundschuh, A de la Chapelle and C D Bloomfield

Leukemia 2017 31: 1474-1476; advance online publication, March 24, 2017; 10.1038/leu.2017.97

Full Text

Advertisement webcasts

Join us for our upcoming webcast followed by live Q&A: 

Presented by BioPharma Dealmakers

Date: Tuesday, 13 June, 2017
Time: 8AM PDT | 11AM EDT | 4PM BST | 5PM CEST


Sponsored by: Immunomic Therapeutics, Inc., | IsoPlexis | Merus N.V. | Actinium Pharmaceuticals, Inc.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at: (You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: